RINGPU(300119) 搜狐财经·2025-04-07 12:35Core Insights - The core viewpoint of the article is that Ruipu Biotech (SZ300119) reported its 2024 annual results, showing a revenue increase but a significant decline in net profit compared to the previous year. Financial Performance - In 2024, Ruipu Biotech achieved operating revenue of 3.07 billion yuan, representing a year-on-year growth of 13.32% [1][2] - The net profit attributable to shareholders was 307 million yuan, a decrease of 33.7% year-on-year [1][2] - The net profit after deducting non-recurring gains and losses was 281 million yuan, down 11.84% from the previous year [1][2] - The net cash flow from operating activities was 736 million yuan, an increase of 79.35% compared to the previous year [2] Earnings Per Share - Basic earnings per share (EPS) for 2024 was 0.6533 yuan, a decline of 33.24% year-on-year [2] - Diluted EPS also stood at 0.6533 yuan, reflecting the same percentage decrease [2] Return on Equity - The weighted average return on equity (ROE) was 6.55%, down 3.68% from the previous year [2] Segment Performance - Revenue from veterinary biological products reached 1.32 billion yuan, up 23.4% year-on-year, with a gross margin of 62.77%, down 2.67% [3] - Revenue from veterinary preparations and raw materials was 1.04 billion yuan, a decrease of 6.37% year-on-year, with a gross margin of 36.67%, down 2.78% [3] - Revenue from the pet supply chain was 633 million yuan, an increase of 37.66% year-on-year, with a gross margin of 14.99%, up 0.89% [3]